Market open
Bionano Genomics/$BNGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bionano Genomics
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Ticker
$BNGO
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
99
ISIN
US09075F4046
Website
Bionano Genomics Metrics
BasicAdvanced
$12M
-
-$88.13
2.09
-
Price and volume
Market cap
$12M
Beta
2.09
52-week high
$6.32
52-week low
$2.68
Average daily volume
163K
Financial strength
Current ratio
1.057
Quick ratio
0.381
Long term debt to equity
10.414
Total debt to equity
77.165
Interest coverage (TTM)
-37.46%
Management effectiveness
Return on assets (TTM)
-32.69%
Return on equity (TTM)
-170.33%
Valuation
Price to revenue (TTM)
0.159
Price to book
0.2
Price to tangible book (TTM)
0.28
Price to free cash flow (TTM)
-0.071
Growth
Revenue change (TTM)
-14.79%
Earnings per share change (TTM)
-78.43%
3-year revenue growth (CAGR)
19.62%
3-year earnings per share growth (CAGR)
-17.51%
Bionano Genomics News
AllArticlesVideos
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewsWire·2 days ago
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers
GlobeNewsWire·1 week ago
Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bionano Genomics stock?
Bionano Genomics (BNGO) has a market cap of $12M as of May 09, 2025.
What is the P/E ratio for Bionano Genomics stock?
The price to earnings (P/E) ratio for Bionano Genomics (BNGO) stock is 0 as of May 09, 2025.
Does Bionano Genomics stock pay dividends?
No, Bionano Genomics (BNGO) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Bionano Genomics dividend payment date?
Bionano Genomics (BNGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bionano Genomics?
Bionano Genomics (BNGO) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.